MDXH (MDxHealth) Insider Ownership: 0.19 % (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDXH MDxHealth SA MDXH
45 GF Score
Price $0.60
GF Value $2.08
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is MDxHealth Insider Ownership?

MDxHealth MDXH -0.55% 45 Insider Ownership is 0.19 % as of Sep. 22, 2026. GuruFocus rates MDXH with a GF Score™ of 45/100 and a GF Value™ of $2.08 (Possible Value Trap). The stock has 6 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, MDxHealth's insider ownership is 0.19%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, MDxHealth's Institutional Ownership is 32.30%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, MDxHealth's Float Percentage Of Total Shares Outstanding is 86.80%.

MDxHealth Insider Ownership Historical Data

* Premium members only.

The historical data trend for MDxHealth's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MDxHealth Insider Ownership Chart

MDxHealth Historical Data

The historical data trend for MDxHealth can be seen below:

2026-05-31 2026-06-30 2026-07-31 2026-08-31
Insider Ownership 0.19 0.19 0.19 0.19
MDXH
45GF Score
MDxHealth SA MDXH
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MDxHealth Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 0.19 % mean?
MDxHealth (MDXH) has a Insider Ownership of 0.19 % as of Sep. 22, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on MDxHealth and its competitors.
Is MDxHealth's Insider Ownership too high?
MDxHealth's current Insider Ownership is 0.19 %. Overall, MDxHealth has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MDxHealth's Insider Ownership compare to PRPO and IDXGD?
MDxHealth's Insider Ownership of 0.19 % can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Medical Diagnostics & Research company?
A good Insider Ownership depends on the Medical Diagnostics & Research industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on MDxHealth and its competitors. MDxHealth's current Insider Ownership is 0.19 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MDxHealth stock overvalued right now?
Based on GuruFocus' analysis, MDxHealth (MDXH) is currently considered Possible Value Trap. The stock's GF Value™ is $2.08, compared to a current price of $0.60 — trading 71.3% below its estimated fair value. The current Insider Ownership is 0.19 %. MDxHealth's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For MDxHealth (MDXH), the current Insider Ownership is 0.19 % as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MDxHealth (MDXH) Overvalued in 2026?

Based on GuruFocus' analysis, MDxHealth stock appears to be undervalued. The current stock price of $0.60 is trading 71.3% below its estimated GF Value™ of $2.08. GuruFocus considers MDxHealth to be Possible Value Trap.

Key valuation signals for MDXH:

  • Insider Ownership: 0.19 %
  • GF Value™: $2.08 vs. price of $0.60 (71.3% below fair value)
  • GF Score™: 45/100 with 6 warning signs

No single metric tells the full story. See the MDXH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MDxHealth Business Description

Other Exchanges O6C1:Germany
Address Zone Industrielle des Hauts-Sarts, Rue d’Abhooz, 31, Cap Business Center, Herstal, Liege, BEL, 4040
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
45GF Score

Get the complete analysis for MDXH

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.60
Price
$2.08
GF Value